Amyris, Inc. plans to acquire Oobli Inc., a Davis, Calif.-based company that develops fermentation-derived sweet proteins for food and beverage makers seeking to reduce sugar without sacrificing taste. Amyris, based in Emeryville, Calif., describes itself as a vertically integrated biomanufacturing company. The acquisition is expected to close in the coming weeks.
The transaction follows Amyris's expansion of manufacturing capacity earlier this year at its advanced fermentation facility in Barra Bonita, Brazil. Amyris framed the acquisition as a commercial and technology expansion that would accelerate its presence in protein- and peptide-based solutions across end markets. It said the deal combines its scientific capabilities and manufacturing depth with Oobli's expertise in protein fermentation.
Sweet-protein platform
Oobli has spent about a decade refining a fermentation process for producing sweet proteins found naturally in rare fruits and berries near the equator. According to the companies, these proteins are hundreds to thousands of times sweeter than sugar, bind directly to sweet taste receptors and are metabolized by the body as protein. Oobli says the ingredients deliver sweetness without gut disruption or blood sugar spikes.
Oobli's commercial portfolio includes Oubli Fruit, Serendipity Berry and Katemfe Fruit Sweet Proteins, known scientifically as brazzein, monellin and thaumatin. The portfolio has FDA GRAS status as an ingredient and is FEMA GRAS-affirmed for use as a natural flavor. Oobli describes its sweet proteins as the first of their kind in the sugar-reduction category. The portfolio is described as applicable across sports and nutrition, dairy, beverages, chocolate, bakery and confectionery as consumer awareness of metabolic health and sugar reduction grows.
Combined capabilities
Amyris CEO Kathy Fortmann said Oobli offers a commercial and technology platform that complements Amyris's own. She said Amyris aims to bring its commercial scale and resources to accelerate what the company calls the sweet revolution. By combining Oobli's protein expertise with Amyris's strain engineering, manufacturing scale and commercial capabilities, Fortmann said the companies see potential to broaden capabilities in food and beverage, personal care, flavor and fragrance, agriculture and other markets.
Oobli CEO Ali Wing said the company had long believed there was a better way to deliver the sweet taste consumers want without trade-offs to health and the environment. She said joining Amyris would provide the scale and resources to pursue Oobli's ambition of making sweet proteins a global standard in sweetness solutions. Fortmann added that Amyris has seen biomanufactured solutions succeed when they align with consumer demand and market needs, and said Oobli's platform addresses sweet taste, sugar reduction and clean label together.
Oobli's sweet protein portfolio is expected to be the first to benefit from the combined platform. Amyris said the portfolio would continue to expand as part of the company, while existing customer commitments and brand partnerships remain uninterrupted.
